ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,255.57
      1.08%
      US Tech 100
      17,632.40
      1.39%
      Dow Jones
      39,048.24
      0.73%
      Brent Oil
      78.08
      -0.38%
      Bitcoin
      57,661.66
      4.78%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Ocugen Inc (OCGN)

      7. Ocugen Inc (OCGN) News

      OCGN

      Ocugen (OCGN)

      Ocugen Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:OCGN
      DateTimeSourceHeadlineSymbolCompany
      08/08/20246:45AMGlobeNewswire Inc.Ocugen Provides Business Update with Second Quarter 2024 Financial ResultsNASDAQ:OCGNOcugen Inc
      08/08/20246:06AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCGNOcugen Inc
      08/05/20247:18AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCGNOcugen Inc
      08/05/20246:30AMGlobeNewswire Inc.Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis PigmentosaNASDAQ:OCGNOcugen Inc
      08/02/20243:22PMGlobeNewswire Inc.Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common StockNASDAQ:OCGNOcugen Inc
      08/01/20249:18AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OCGNOcugen Inc
      08/01/20249:16AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCGNOcugen Inc
      07/31/20249:15PMGlobeNewswire Inc.Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common StockNASDAQ:OCGNOcugen Inc
      07/31/20244:16PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OCGNOcugen Inc
      07/31/20244:15PMGlobeNewswire Inc.Ocugen, Inc. Announces Proposed Public Offering of Common StockNASDAQ:OCGNOcugen Inc
      07/29/20247:02AMGlobeNewswire Inc.Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial ResultsNASDAQ:OCGNOcugen Inc
      07/25/20246:30AMGlobeNewswire Inc.Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene TherapyNASDAQ:OCGNOcugen Inc
      07/08/20244:31PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCGNOcugen Inc
      06/21/20247:00AMGlobeNewswire Inc.Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt DiseaseNASDAQ:OCGNOcugen Inc
      06/20/20246:30AMGlobeNewswire Inc.Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa IndicationNASDAQ:OCGNOcugen Inc
      06/18/20244:29PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:OCGNOcugen Inc
      06/06/20244:31PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCGNOcugen Inc
      05/31/20248:36AMGlobeNewswire Inc.Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic AtrophyNASDAQ:OCGNOcugen Inc
      05/29/20247:15AMGlobeNewswire Inc.Ocugen to Present at BIO International Convention 2024NASDAQ:OCGNOcugen Inc
      05/28/20244:05PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:OCGNOcugen Inc
      05/28/20247:02AMGlobeNewswire Inc.Ocugen Set to Join Russell 3000® Index Effective June 28, 2024NASDAQ:OCGNOcugen Inc
      05/20/20247:00AMGlobeNewswire Inc.Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024NASDAQ:OCGNOcugen Inc
      05/17/20244:30PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:OCGNOcugen Inc
      05/15/20246:30AMGlobeNewswire Inc.Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene TherapyNASDAQ:OCGNOcugen Inc
      05/14/20243:54PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCGNOcugen Inc
      05/14/20248:00AMGlobeNewswire Inc.Ocugen Provides Business Update with First Quarter 2024 Financial ResultsNASDAQ:OCGNOcugen Inc
      05/14/20247:18AMIH Market NewsUS Futures Remain Steady Amid Wall Street Caution Ahead of April PPI ReportNASDAQ:OCGNOcugen Inc
      05/14/20246:32AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCGNOcugen Inc
      05/10/20244:15PMEdgar (US Regulatory)Form 8-A12G - Registration of securities [Section 12(g)]NASDAQ:OCGNOcugen Inc
      05/10/20244:14PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCGNOcugen Inc
       Showing the most relevant articles for your search:NASDAQ:OCGN

      Your Recent History

      EU
      EDP
      EDP
      Delayed Upgrade Clock